FDA Drug Master
Files (DMF) Services
An FDA Drug Master File (DMF) is a voluntary submission used to provide FDA with confidential, detailed information about facilities, processes, or materials used in the manufacture, processing, packaging, or storage of human drug products. DMFs are provided for under 21 CFR 314.420. They let a holder authorize an applicant or sponsor to rely on specified DMF information without disclosing the confidential contents to that party. FDA does not approve or disapprove a DMF; it reviews the relevant technical content when an application references the file.
FDA Registration Assistance helps prepare, format, submit, and maintain Drug Master Files while protecting the holder’s confidential technical information and supporting authorized references from applicable FDA drug submissions.
What Is a Drug Master File (DMF) & Who Needs One
A Drug Master File (DMF) is a voluntary submission to FDA that can contain confidential, detailed information about facilities, processes, materials, or articles used in the manufacture, processing, packaging, or storage of human drugs. A DMF is commonly used when a supplier wants FDA to review proprietary technical information without disclosing that information to the applicant or sponsor that relies on it.
FDA ordinarily does not independently review, approve, or disapprove a DMF. Instead, FDA reviews relevant DMF content in connection with an application that references it. FDA Registration Assistance supports preparation, eCTD publishing, electronic submission, Letters of Authorization, annual updates, amendments, and related DMF lifecycle work.
- Voluntary submission — not an FDA approval, license, or substitute for an NDA, ANDA, IND, or other application
- Protects proprietary technical information while allowing authorized FDA reference
- Current FDA DMF types are Type II, Type III, Type IV, and Type V; Type I has been discontinued
- FDA reviews relevant DMF content when it is referenced in an applicable submission
- DMF holders should keep the file current and maintain authorization information throughout its lifecycle
Our Drug Master File (DMF) Services
Everything drug manufacturers need to prepare, submit, and maintain a compliant FDA Drug Master File — handled by experienced FDA regulatory specialists.
DMF Preparation
We organize the administrative package and technical content appropriate to the DMF type, identify information gaps, and prepare the submission for FDA-compatible electronic filing.
Electronic Submission & Acknowledgment
We support eCTD publishing and electronic transmission to FDA, then track the administrative acknowledgment and assigned DMF number.
Letter of Authorization (LOA) Support
We prepare Letters of Authorization that identify the holder, authorized party, DMF number, and the information being authorized for reference, consistent with FDA requirements and guidance.
DMF Maintenance & Amendments
We support annual updates, administrative and quality amendments, holder or agent changes, LOA updates or withdrawals, and responses to FDA DMF correspondence.
Trusted FDA Drug Master File Specialists
Regulatory support for U.S. and foreign drug companies, API manufacturers, excipient suppliers, and packaging-material suppliers.
How Our DMF Preparation & Submission Service Works
A four-step workflow for preparing, submitting, and maintaining a Drug Master File while keeping the holder in control of the confidential technical record.
Submit Your Technical Information
Provide available facility, process, material, specification, and quality documentation. We review the package to determine the appropriate DMF type and identify missing content.
DMF Compiled & Reviewed
We organize the administrative and technical content, prepare the eCTD structure where applicable, and perform a pre-submission completeness and consistency review.
DMF Submitted to FDA
We support electronic transmission to FDA and track the administrative acknowledgment and assigned DMF number.
LOAs, Updates & Maintenance
After filing, we can support Letters of Authorization, annual updates, amendments, transfer or agent changes, and responses to FDA correspondence as needed.
Core DMF Holder Responsibilities & FDA Lifecycle Expectations
DMF holders should maintain accurate technical content, authorization records, and FDA contact information so the file remains usable when an applicant or sponsor relies on it.
Use FDA’s Electronic Submission Standards
For CDER human-drug DMFs, eCTD is FDA’s standard electronic format. The submission must be organized and transmitted in accordance with the applicable FDA electronic-submission specifications.
Maintain FDA Contact / Agent Information
FDA guidance allows a holder to appoint an agent or representative and encourages foreign DMF holders to engage a U.S. agent. If an agent is appointed, the holder should file the appointment and define the agent’s scope of responsibility.
Maintain Complete Type-Specific Technical Content
The technical content depends on the DMF type. Type II drug-substance files generally contain detailed manufacturing, characterization, controls, container-closure, and stability information; other DMF types have their own content expectations.
Issue Accurate Letters of Authorization
Written authorization is required before an applicant or sponsor can incorporate DMF information by reference. The authorization should clearly identify the holder, DMF, authorized party, and information covered.
Provide the FDA Annual Update Described in Guidance
FDA’s DMF guidance says the holder should provide an annual update on the anniversary date of the original submission, including current authorization information and changes since the prior annual update.
Submit Amendments When Information Changes
When information in the DMF is added, changed, or deleted, the holder must submit the change to FDA and notify each affected person authorized to reference that information as required by 21 CFR 314.420(c).
Pay GDUFA DMF Fees When They Apply
Only certain Type II API DMFs used in generic drug submissions incur the GDUFA DMF fee. The fee is one-time for the qualifying DMF and is separate from professional preparation or maintenance fees.
Respond to FDA DMF Correspondence
When FDA reviews a DMF in connection with a referencing application, the holder may receive deficiency or information requests. Prompt, technically complete responses help prevent avoidable delays to the referencing application.
Drug Master File (DMF) vs. Abbreviated New Drug Application (ANDA)
A DMF is a confidential reference file; an ANDA is a marketing application for a generic drug. FDA may review DMF content in support of the ANDA, but the DMF itself is not approved.
| Attribute | Drug Master File (DMF) | Abbreviated New Drug Application (ANDA) |
|---|---|---|
| Who Files It | A DMF holder such as an API/drug-substance manufacturer, excipient supplier, packaging supplier, or other owner of confidential technical information | The applicant seeking approval to market a generic finished drug product |
| What It Represents | Confidential technical information that an authorized applicant can incorporate by reference without receiving the confidential contents | A marketing application containing the information required to establish that the proposed generic drug meets FDA requirements |
| Required By | DMFs are voluntary; they are not required by statute or regulation | An ANDA is the statutory pathway under section 505(j) of the FD&C Act for approval of qualifying generic drugs |
| Governing Regulation | 21 CFR 314.420 | 21 CFR Part 314, including 21 CFR 314.94 |
| Primary Function | Protects confidential technical information while allowing FDA to review it when an authorized application relies on the DMF | Seeks FDA approval for the generic finished drug product |
| Outcome of FDA Review | FDA neither approves nor disapproves the DMF; status and, for certain Type II API DMFs, availability-for-reference are separate concepts | FDA may approve, tentatively approve, or issue a Complete Response Letter depending on the application |
A DMF and an ANDA can work together without serving the same purpose. A Type II API DMF may supply confidential drug-substance information that an ANDA applicant is authorized to reference. For generic drug submissions, a qualifying Type II API DMF must satisfy applicable GDUFA fee and availability-for-reference requirements before it can support the ANDA.
In-House DMF Preparation vs. FDA Registration Assistance
Companies can prepare and maintain a DMF internally, but the work requires coordinated technical authoring, electronic publishing, lifecycle management, and FDA correspondence.
| Factor | In-House / DIY Preparation | Recommended FDA Registration Assistance |
|---|---|---|
| Cost | Internal staff time, technical-authoring resources, eCTD publishing capability, and any applicable FDA user fees | Custom professional quote based on DMF type, documentation volume, publishing complexity, and maintenance scope; FDA government fees are separate |
| Availability | Depends on internal regulatory, quality, CMC, and publishing resources | A dedicated regulatory support workflow for preparation, submission, acknowledgment tracking, LOAs, updates, and amendments within the agreed scope |
| Domain Expertise | Requires knowledge of 21 CFR 314.420, FDA DMF guidance, eCTD standards, applicable CTD quality content, and GDUFA rules where relevant | FDA regulatory support informed by current DMF submission resources, eCTD requirements, and drug-compliance experience |
| Risk of Failure | Quality depends on the completeness of the technical package, correct DMF type, valid electronic structure, and lifecycle controls | Pre-submission review can identify administrative, content, and eCTD issues before transmission |
| Confirmation & Handling | Internal staff must track FDA acknowledgment, DMF number, public-list information, LOAs, and subsequent correspondence | Acknowledgment and DMF-number tracking plus support for authorization and follow-up correspondence |
| Annual Report & Update Tracking | The holder should track the anniversary-based annual update described in FDA guidance and submit amendments when information changes | Annual-update and amendment support can be included in the quoted maintenance scope |
The legal DMF holder remains responsible for the accuracy and currency of its file regardless of who assists with preparation or transmission. Professional support is most useful when the holder needs coordinated CMC organization, eCTD publishing, LOA administration, annual updates, amendments, or responses to FDA correspondence.
Informal / Third-Party Filing vs. FDA Registration Assistance
A third party can assist with preparation or electronic transmission, but the named DMF holder—not the person who clicks “submit”—owns and controls the DMF. The filing should accurately identify the holder and authorized FDA contact from the beginning.
| Factor | Informal / Third-Party Assistance | Recommended FDA Registration Assistance |
|---|---|---|
| Government Fee | Types III, IV, and V do not incur the GDUFA Type II API DMF fee; qualifying Type II API DMFs can incur a separate FDA user fee | Professional service fee is custom-quoted; applicable FDA government fees remain separate |
| Pros | A capable internal colleague, consultant, agent, or publishing vendor can assist the holder without changing who owns the DMF | Structured preparation, holder-identity review, eCTD support, acknowledgment tracking, LOA support, and optional lifecycle maintenance |
| Cons | Risk increases when holder identity, contact authority, technical responsibilities, or document ownership are unclear; using another party’s ESG account does not itself transfer DMF ownership | Professional assistance does not replace the holder’s responsibility for complete and accurate technical information |
| Best For | Organizations that already have qualified CMC/regulatory staff and clear control over the holder record, technical content, and FDA correspondence | Holders that want coordinated regulatory and publishing support while keeping the DMF under the correct legal entity |
The key issue is not whether an employee, consultant, agent, or vendor helps transmit the submission. The key is that the DMF correctly identifies the holder, preserves the holder’s control over Letters of Authorization and future amendments, and maintains reliable FDA correspondence and records.
Drug Master File Terms You Will Encounter
A quick reference of the technical terms, document types, and submission systems used throughout the FDA Drug Master File process.
The FDA-assigned identifier for a Drug Master File. It is used on subsequent submissions, Letters of Authorization, annual updates, and amendments associated with that file.
Type II covers a drug substance, drug-substance intermediate, material used in their preparation, or a drug product. GDUFA fee and completeness-assessment provisions apply specifically to certain Type II API DMFs used in generic drug submissions.
A DMF category for packaging material information that a manufacturer may keep confidential while authorizing an applicant or sponsor to reference it.
A DMF category for an excipient, colorant, flavor, essence, or material used in their preparation, including applicable manufacturing, specification, and testing information.
FDA-accepted reference information that does not fit Types II through IV. FDA expects the prospective holder to contact the DMF staff before submitting a Type V DMF.
Written authorization from the holder permitting FDA to refer to specified DMF information in support of another person’s submission. The authorization should identify the holder, DMF, authorized party, and the information covered.
FDA’s DMF guidance says the holder should provide an annual update on the anniversary date of the original submission, including current authorization information and changes made since the previous annual update.
FDA’s standard electronic submission format for CDER regulatory submissions, including DMFs. FDA supports eCTD v3.2.2 and v4.0 in accordance with its current standards and implementation timelines.
FDA’s electronic transmission gateway for regulatory submissions, including eCTD submissions to CDER.
A one-time FDA user fee that applies to qualifying Type II API DMFs used in generic drug submissions. The fee is separate from professional DMF preparation or maintenance fees and changes by fiscal year.
FDA’s public quarterly list showing DMF number, type, subject, holder, and activity status for files included in the current release. Separate GDUFA resources identify Type II API DMFs available for reference.
A lifecycle submission used when ownership of a DMF changes. FDA’s DMF guidance and templates describe letters from the former and new holder and continuation under the existing DMF number.
Common DMF Problems That Delay Review or Affect Status
Common DMF problems usually involve stale information, incomplete technical content, authorization defects, electronic-submission errors, or GDUFA requirements that apply to certain Type II API DMFs.
Annual Update Not Maintained
FDA guidance says holders should submit an annual update on the anniversary date. Failure to keep a DMF current can delay review of a referencing application and may lead FDA to initiate closure procedures; it is not accurate to say one missed update automatically makes every DMF inactive.
Incomplete Type-Specific Technical Content
For Type II drug-substance DMFs, gaps in applicable CTD quality sections can lead to FDA questions when a referencing application is reviewed. Other DMF types have their own technical-content expectations.
Unpaid GDUFA Type II API DMF Fee
When the GDUFA DMF fee becomes due for a qualifying Type II API DMF, the DMF is not available for reference until the applicable fee and completeness-assessment requirements are satisfied.
Incorrect or Missing Letter of Authorization
FDA cannot rely on DMF information for another person’s submission unless the holder has provided written authorization that identifies the authorized reference and covered information.
eCTD Validation or Publishing Errors
Technical validation errors, incorrect lifecycle handling, or misplaced content can prevent clean electronic processing and create avoidable submission delays.
Unclear FDA Contact or Agent Information
A DMF-specific U.S. agent is not mandatory. FDA guidance encourages foreign DMF holders to engage a U.S. agent, and any appointed agent or representative should be clearly identified with the scope of responsibility.
Poor DMF Lifecycle Control
Creating unnecessary duplicate files or failing to amend the correct existing DMF can complicate references and FDA correspondence. Changes should be managed through the appropriate lifecycle submission for the existing file when applicable.
Claiming "FDA-Approved" Based on the DMF
FDA does not approve or disapprove DMFs. Marketing a DMF, API, material, or facility as “FDA-approved” merely because a DMF exists is inaccurate.
Complete FDA Drug Registration Solutions
We offer a full range of FDA registration and compliance services to help your facility and shipments meet all U.S. regulatory requirements.
Drug Establishment Registration
FDA drug establishment registration and annual renewal assistance for applicable domestic and foreign establishments — $449/year professional service.
Labeler Code Registration
Labeler Code request assistance for companies that need an FDA labeler code for drug listing/NDC submissions — $349 one-time professional service.
NDC Code / Product Code
NDC product-listing assistance for applicable drug products, including SPL preparation and submission — $199 per product.
Drug Label & Ingredient Review
Drug label and ingredient compliance review for applicable OTC and prescription drug labeling requirements — $249 per label review.
DUNS Request Assistance
DUNS request and verification assistance for drug-registration and listing workflows — $399 one-time professional service.
Drug / OTC U.S. Agent Services
Annual U.S. Agent service for foreign drug establishments that must designate a U.S. Agent as part of FDA drug establishment registration — $849/year.
FDA Drug Listing Certificate
Professional listing-verification document prepared from applicable FDA registration and drug-listing records. Custom quote; not an FDA approval certificate.
FDA Drug Master Files (DMF)
Custom-quoted DMF preparation, eCTD submission support, Letters of Authorization, annual updates, amendments, and lifecycle assistance.
Drug Import Alert Removal
Custom-quoted regulatory support for FDA drug import alerts, detentions, and related corrective-action or removal strategies.
Frequently Asked Questions — FDA Drug Master Files (DMF)
Find answers to the most common questions about FDA Drug Master Files, DMF preparation, submission, and how FDA Registration Assistance supports drug manufacturers worldwide.
What is a Drug Master File (DMF)?
A Drug Master File (DMF) is a voluntary submission to FDA used to provide confidential, detailed information about facilities, processes, materials, or articles used in the manufacture, processing, packaging, or storage of human drugs. It allows authorized applicants or sponsors to rely on specified information without receiving the confidential DMF contents.
Is a DMF required by the FDA?
No. FDA states that DMFs are not required by statute or regulation. They are voluntary and are commonly used when a holder wants FDA to review confidential technical information in support of another submission without disclosing that information to the party relying on it.
Does the FDA approve or disapprove DMFs?
No. FDA neither approves nor disapproves a DMF. FDA ordinarily reviews relevant DMF content only in connection with an application or submission that is authorized to reference it.
What types of information are included in a DMF?
The content depends on the DMF type. It may include information about drug substances or intermediates, drug products, packaging materials, excipients, colorants, flavors, or other FDA-accepted reference information, together with the administrative and technical material needed for the specific file.
Who can reference a DMF?
A person may incorporate DMF information by reference only when the DMF holder has authorized that reference in writing. The authorization should identify the holder, DMF, authorized party, and the information covered by the authorization.
What applications can reference a DMF?
DMFs are commonly used to support applicable INDs, NDAs, ANDAs, amendments, supplements, and certain other FDA submissions. Biologics master-file referencing can be subject to additional CBER rules, so the correct reference pathway should be confirmed for the specific product and application.
What are the different types of DMFs?
FDA currently recognizes Type II, Type III, Type IV, and Type V DMFs. Type II covers drug substances, drug-substance intermediates, materials used in their preparation, or drug products; Type III covers packaging materials; Type IV covers excipients, colorants, flavors, essences, or materials used in their preparation; and Type V is for FDA-accepted reference information. Type I has been discontinued.
How long does DMF preparation take?
Preparation time depends on DMF type, technical-documentation readiness, CMC complexity, publishing requirements, and the number of gaps that must be resolved before filing. FDA Registration Assistance provides a project timeline after reviewing the available documentation; complex Type II files can require substantially more work than simpler administrative or reference packages.
How much does DMF preparation cost?
DMF preparation is custom-quoted because the scope varies significantly by DMF type, technical-documentation volume, eCTD publishing complexity, and lifecycle-support needs. Applicable FDA government user fees, including GDUFA fees for qualifying Type II API DMFs, are separate from professional service fees.
Do DMFs need to be updated?
Yes. The holder must keep the DMF current, submit changes to FDA when information is added, changed, or deleted, and notify affected authorized parties as required by 21 CFR 314.420(c). FDA guidance also describes an annual update on the anniversary date of the original submission.
What is a Letter of Authorization (LOA)?
A Letter of Authorization is the holder’s written authorization permitting FDA to refer to specified information in the DMF in support of another person’s submission. The referencing applicant or sponsor should also receive a copy for inclusion with its submission.
Can foreign companies submit a DMF to the FDA?
Yes. Foreign companies can hold and submit DMFs. FDA guidance encourages foreign DMF holders to engage a U.S. agent, but a DMF-specific U.S. agent is not mandatory. If an agent is appointed, the holder should submit the appointment and define the agent’s scope of responsibility.
How is a DMF submitted to the FDA?
For CDER human-drug DMFs, eCTD is FDA’s standard electronic format and submissions are transmitted electronically through FDA’s Electronic Submissions Gateway. FDA provides DMF-specific submission resources, templates, and instructions for original and subsequent submissions.
What happens after the DMF is submitted?
FDA examines an original DMF submission for administrative acceptability. If acceptable, FDA acknowledges receipt and assigns a DMF number. FDA ordinarily does not review the technical contents until the DMF is referenced in connection with an applicable submission.
Can FDA Registration Assistance respond to FDA DMF deficiency letters?
Yes. FDA Registration Assistance can support responses to DMF deficiency or information requests by coordinating the technical response, preparing the appropriate amendment or response package, and assisting with electronic submission within the agreed project scope.
Does FDA Registration Assistance assist with the full drug registration process?
Yes. In addition to DMF services, FDA Registration Assistance offers drug establishment registration, Labeler Code assistance, NDC product listing, DUNS assistance, annual U.S. Agent services, drug label review, and professional drug-listing verification services.
Why is DMF pricing custom-quoted instead of a flat fee, and how does it fit alongside Drug Establishment Registration, Labeler Code, and NDC services?
A DMF can range from a relatively focused reference file to a large Type II technical dossier with extensive CMC documentation and publishing work, so the professional fee is custom-quoted. DMF work is separate from routine establishment registration, Labeler Code, NDC listing, DUNS, U.S. Agent, and label-review services. Any applicable FDA government DMF fee is also separate.
Can a friend or unrelated party file my Drug Master File for me?
A third party can assist with preparation or electronic transmission, but the legal DMF holder is the entity identified as the holder in the submission. Using another person’s ESG account does not by itself make that person the DMF owner. The important issue is to identify the correct holder, authorized contact or agent, and scope of representation from the beginning.
What happens if I do not respond to an FDA deficiency letter on my DMF?
If FDA identifies deficiencies in a DMF being reviewed in connection with a referencing application, an incomplete or late response can delay review of that application. The consequences depend on the type of DMF, the issue identified, and the referencing submission; they are not automatically the same for every DMF.
How do I update or change information in an existing DMF?
Changes are generally submitted to the existing DMF as the appropriate administrative or quality amendment using the same DMF number. FDA’s templates identify amendment categories for changes such as holder or agent information, facilities, manufacturing information, controls, packaging, stability, and other quality content. FDA guidance also describes annual updates and transfer procedures.
Do I need a DMF to sell my OTC drug, supplement, or finished product on Amazon?
A DMF is generally not a retail-marketplace requirement. DMFs are used to support FDA regulatory submissions by protecting confidential technical information. Separate FDA establishment registration, drug listing, NDC, labeling, or other requirements may apply depending on the product and the activities of the companies involved.
Does having a DMF mean my drug, API, or facility is FDA-approved?
No. FDA expressly states that DMFs are neither approved nor disapproved. A DMF number, an Active listing, or availability-for-reference does not mean FDA has approved the DMF holder, API, material, facility, or finished product.
What is the difference between a Type II API DMF and an ANDA?
A Type II API DMF can contain confidential information about the manufacture and control of a drug substance. An ANDA is the application seeking FDA approval for a generic finished drug product. An ANDA may reference an authorized Type II API DMF, but the DMF itself is not the marketing application and is not approved.
Are excipient and packaging-material DMFs subject to GDUFA fees?
The GDUFA DMF fee applies to qualifying Type II API DMFs used in generic drug submissions. Type III packaging and Type IV excipient DMFs do not incur the Type II API DMF fee simply because they are DMFs. FDA publishes the applicable DMF fee for each fiscal year.
How do I verify whether a Drug Master File is active and listed with the FDA?
FDA publishes a List of DMFs that is updated quarterly and includes the DMF number, type, subject, holder, and activity status for files included in the release. For Type II API DMFs under GDUFA, FDA also maintains a separate available-for-reference list. 'Active' and 'available for reference' are not interchangeable terms.
Does my DMF need a U.S. Agent if my company is outside the United States?
FDA’s DMF guidance encourages foreign DMF holders to engage a U.S. agent, but it does not make a DMF-specific U.S. agent mandatory. A holder may appoint an agent or representative as the FDA contact; when appointed, the holder should submit a signed appointment identifying the agent and scope of responsibility.
Can a single Drug Master File cover multiple APIs or multiple facilities?
FDA guidance says a DMF should generally contain one type of information and a Type II DMF should generally be limited to a single drug intermediate, drug substance, drug product, or type of material used in preparation. Multiple facilities may be described when they are relevant to the same DMF subject, but unrelated subjects usually require separate filing strategies.
What is the difference between an Active DMF and an Inactive DMF?
FDA’s public DMF list uses activity-status designations, while GDUFA also has a separate 'available for reference' concept for qualifying Type II API DMFs. An inactive file should be evaluated to determine why its status changed and what submission, update, or other action FDA requires before it can support future references.
How do I transfer ownership of a DMF when my company is acquired?
FDA guidance provides a transfer-of-ownership process. The former holder should notify FDA and authorized persons, and the new holder should submit a letter accepting the transfer and update applicable DMF information. The existing DMF number is generally retained through the transfer process.
Can I use a DMF to support a Type A or Type B Pre-IND meeting with the FDA?
A sponsor may be able to rely on relevant DMF information in connection with an FDA interaction when the holder has provided appropriate authorization, but the meeting package and reference strategy should be tailored to the specific product, submission, and FDA center. The DMF itself is not the meeting request or meeting package.
Get Your Drug Master File Prepared Today
Tell us your DMF type, technical-documentation status, and intended FDA use. We’ll review the scope and respond with the information needed for a custom quote.
Thank You for Reaching Out!
Your message was submitted successfully. Our team will follow up regarding your Drug Master File request. For immediate assistance, use the phone or email options below.